Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the HIV Prevention topic
No spam. Unsubscribe anytime.
Committee hears debate on requiring pharmacy‑benefit pathway for injectable PrEP
Summary
SB 1023 would require insurers that cover long‑acting injectable PrEP under medical benefits to also cover it under pharmacy benefits to ease clinic access; advocates said current billing blocks rollout while health plans warned the bill intrudes on benefit design and could create administrative burdens.
On behalf of Sen. Laird, the committee heard SB 1023 to make insurers that cover long‑acting injectable PrEP through a medical benefit also provide a pharmacy‑benefit pathway to support timely administration. Jonathan Froxweig, director of health justice policy at the San Francisco AIDS Foundation, said the state’s progress against new HIV infections has stalled and that insurer billing practices are creating barriers. "In the last year for which data is available, almost 5,000 Californians were newly diagnosed with HIV," Froxweig told the committee, and he said clinics are turning patients away when insurers limit injectable PrEP to medical‑benefit billing.
Opposition witnesses from the California Association of Health Plans and the Association of California Life and Health Insurance Companies argued the bill sets a precedent by dictating benefit design and could undermine clinical and actuarial judgment. Cassidy Heckman (California Association of Health Plans) said plans already cover these drugs and that SB 1023 "sets a concerning precedent regarding a plan's ability to structure their own benefits." Matt Akin (insurance industry) added the bill could blur the long‑standing administrative distinction between medical and pharmacy benefits and create operational challenges.
Committee members asked clarifying questions about how injectable PrEP would be administered and whether the policy would delay treatment or improve access; sponsors said the bill would not change clinical administration and would only change the billing pathway. The committee moved the bill and placed it on call pending final roll, with a recorded committee tally entered during the hearing.
